Press "Enter" to skip to content

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s steps on naming of biological medicines to balance competition and safety for patients receiving these products

FDA updates draft guidance to set a clear path for the nonproprietary naming of interchangeable biosimilars.

Also Read:   Coronavirus (COVID-19) Update: Daily Roundup July 8, 2020